Surgical Heart Valves
2022 Coding and Reimbursement

This information is provided for your consideration. It is the provider’s responsibility to determine and submit appropriate codes, modifiers, and charges for the services rendered.

Copyright Notice: CPT codes, descriptions and other data only are copyright 2022 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Disclaimer Fee schedules, relative value units, conversion factors and/or related components aren’t assigned by the AMA, aren’t part of CPT, and the AMA isn’t recommending their use. The AMA doesn’t directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Surgical valves physician coding (select codes related to Medtronic surgical valves)

<table>
<thead>
<tr>
<th>Valve product</th>
<th>Composition</th>
<th>Site</th>
<th>CPT code (physician)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aortic and mitral positions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avalus™ Bioprosthesis</td>
<td>Bioprosthesis (stented tissue valve)</td>
<td>Aortic only</td>
<td>33405 (aortic)</td>
</tr>
<tr>
<td>Mosaic™, Mosaic Ultra™</td>
<td>Bioprosthesis (stented tissue valve)</td>
<td>Aortic or mitral</td>
<td>33405 (aortic) 33430 (mitral)</td>
</tr>
<tr>
<td>Hancock™ II, Hancock II Ultra™</td>
<td>Bioprosthesis (stented tissue valve)</td>
<td>Aortic or mitral</td>
<td>33405 (aortic) 33430 (mitral)</td>
</tr>
<tr>
<td>Medtronic Open Pivot™</td>
<td>Mechanical</td>
<td>Aortic or mitral</td>
<td>33405 (aortic) 33430 (mitral)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Valve product</th>
<th>Composition</th>
<th>Site</th>
<th>CPT code (physician)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aortic root</strong> – for replacement of malfunctioning native or prosthetic aortic valves with the option of aortic root replacement**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freestyle™ Aortic Root Bioprosthesis</td>
<td>Bioprosthesis (stentless tissue valve)</td>
<td>Aortic valve only (with aortic root)</td>
<td>33410 if coronary arteries are not involved and aortic root is not replaced or 33410-22 if coronary artery reimplantation is performed or 33863 if aortic root replaced, including coronary artery reimplantation in addition to an ascending aorta graft.</td>
</tr>
</tbody>
</table>

Modifier -22: increased procedural service.

Medtronic CardioVascular Reimbursement Hotline: 1-866-616-8400

†CPT® is a registered trademark of the American Medical Association.
## Surgical valves payment

<table>
<thead>
<tr>
<th>CPT code</th>
<th>CPT description</th>
<th>2022 Work RVUs</th>
<th>2022 Total Facility RVUs</th>
<th>2022 Medicare National Unadjusted Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>33405</td>
<td>Replacement, aortic valve, with cardiopulmonary bypass; with prosthetic valve other than homograft or stentless valve</td>
<td>41.32</td>
<td>66.61</td>
<td>$2,305</td>
</tr>
<tr>
<td>33410</td>
<td>Replacement, aortic valve, with cardiopulmonary bypass; with stentless tissue valve</td>
<td>46.41</td>
<td>74.51</td>
<td>$2,579</td>
</tr>
<tr>
<td>33430</td>
<td>Replacement, mitral valve, with cardiopulmonary bypass</td>
<td>50.93</td>
<td>82.19</td>
<td>$2,844</td>
</tr>
<tr>
<td>33863</td>
<td>Ascending aorta graft, with cardiopulmonary bypass, with or without valve suspension; with aortic root replacement using composite prosthesis and coronary reconstruction</td>
<td>58.79</td>
<td>92.21</td>
<td>$3,191</td>
</tr>
</tbody>
</table>

All Medicare rates displayed in this table reflect the “national unadjusted” amounts inclusive of beneficiary cost-sharing and do not reflect any additional payment adjustments, such as the 2% sequester reduction mandated by the Budget Control Act of 2011 or the 4% PAYGO reduction triggered by the American Rescue Plan in December 2020. Please note that on December 10, 2021, legislation was enacted to delay the 2% sequestration for 3 months (January 1–March 31, 2022), followed by a reduction of 1% for 3 months (April 1–June 30, 2022). The full 2% sequestration cut will go back into effect on July 1, 2022. The 4% PAYGO reduction was postponed through January 1, 2023.

---


### Reimbursement disclaimer

Medtronic does not represent or guarantee that this information is complete, accurate, or applicable to any particular patient or third party payer. Medtronic disclaims all liability for any consequence resulting from reliance on this document. The final decision of billing for any service must be made by the health care provider considering the medical necessity of the service furnished as well as the requirements of third-party payers and any local, state, or federal laws and regulations that apply. Medtronic is providing this information in an educational capacity with the understanding that Medtronic is not engaged in rendering accounting, or other professional services. Medtronic encourages all health care providers to consult with their own advisors regarding coding and payment. All Medicare rates displayed in this document reflect the “national unadjusted” amounts inclusive of beneficiary cost-sharing and do not reflect any additional payment adjustments, such as the 2% sequester reduction mandated by the Budget Control Act of 2011 or the 4% PAYGO reduction triggered by the American Rescue Plan in December 2020. Please note that on December 10, 2021, legislation was enacted to delay the 2% sequestration for 3 months (January 1–March 31, 2022), followed by a reduction of 1% for 3 months (April 1–June 30, 2022). The full 2% sequestration cut will go back into effect on July 1, 2022. The 4% PAYGO reduction was postponed through January 1, 2023. Medtronic doesn’t offer products with approved indications for all procedures listed. For more information, contact the Cardiovascular Health Economics, Policy & Reimbursement Team.
brief statements

avalus™ bioprosthesis

indications:
the avalus bioprosthesis is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic valves.

contraindications:
none.

warnings/precautions/adverse events:
only physicians who have received proper training in valve replacement should use this device. accelerated structural deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, or hyperparathyroidism). adverse events can include: angina, cardiac dysrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, infection other than endocarditis, transvalvular or paravalvular leak, myocardial infarction, nonstructural valve dysfunction (leaflet entrapment/imparing, obstructive pannus ingrowth, suture dehiscence, inappropriate sizing or positioning, or other), pericardial effusion or tamponade, prosthesis regurgitation, prosthesis stenosis, prosthesis thrombosis, stroke, structural valve deterioration (calcification, leaflet tear or perforation, or other), thromboembolism, tissue dehiscence, and transient ischemic attack. these complications could lead to reoperation, explant of the bioprosthesis, permanent disability, or death.

cautions:

For additional information, please refer to the instructions for use provided with the product.

for a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the instructions for use. for countries that use eIFUs, consult instructions for use at medtronic.com/manuals (opens new window).

note: manuals can be viewed using a current version of any major internet browser.

osaic™ bioprosthesis

indications:
for the replacement of malfunctioning native or prosthetic aortic and/or mitral heart valves.

contraindications:
none.

warnings/precautions/adverse events:
accelerated deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). adverse events can include: angina, cardiac dysrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, transvalvular or paravalvular leak, myocardial infarction, nonstructural dysfunction, stroke, structural deterioration, thromboembolism, or valve thrombosis.

cautions:

For federal law (USA) restricts this device to sale by or on the order of a physician.

for a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the instructions for use. for countries that use eIFUs, consult instructions for use at this website medtronic.com/manuals (opens new window).

note: manuals can be viewed using a current version of any major internet browser.

open pivot™ mechanical heart valve

indications:
the medtronic open pivot™ heart valve is indicated for the replacement of diseased, damaged, or malfunctioning native or prosthetic aortic or mitral valves.

contraindications:
the medtronic open pivot heart valve is contraindicated in patients unable to tolerate anticoagulation therapy.

potential adverse events:
adverse events potentially associated with the use of prosthetic heart valves include: cardiac arrhythmias, death, leaflet entrapment/imparing, endocarditis, hemolysis, anticoagulant-related hemorrhage, transvalvular or perivalvular leak, prosthesis thrombosis, structural deterioration, valve thromboembolism.

cautions:

For federal law (USA) restricts this device to sale by or on the order of a physician or properly licensed practitioner. refer to the instructions for use packaged with each valve for a complete listing of warnings and precautions.

freeStyle™ aortic root bioprosthesis

indications:
for the replacement of malfunctioning native or prosthetic aortic valves with the option of aortic root replacement.

contraindications:
none known.

warnings/precautions/adverse events:
accelerated deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). adverse events can include: cardiac dysrhythmias, death, endocarditis, hemolysis, hemorrhage, transvalvular or paravalvular leak, nonstructural dysfunction, structural deterioration, thromboembolism, valve thrombosis, or intracapsular hematoma. for additional information, please refer to the instructions for use provided with the product.

cautions:

For federal law (USA) restricts this device to sale by or on the order of a physician.

Hancock™ II and Hancock II Ultra™ bioprosthesis

indications:
for patients who require replacement of their native or prosthetic aortic and/or mitral valves.

contraindications:
none known.

warnings/precautions/adverse events:
accelerated deterioration due to calcific degeneration of bioprosthesis may occur in: children, adolescents, young adults, and patients with altered calcium metabolism (e.g., chronic renal failure, hyperparathyroidism). adverse events can include: angina, cardiac arrhythmia, cardiac dysrhythmias, death, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, transvalvular or paravalvular leak, myocardial infarction, nonstructural dysfunction, stroke, structural deterioration, thromboembolism, or valve thrombosis.

for additional information, please refer to the instructions for use provided with the product.

cautions:

For federal law (USA) restricts this device to sale by or on the order of a physician.

Medtronic CardioVascular Reimbursement Hotline: 1-866-616-8400